🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsDosing & ProtocolsWhen to hold at a dose vs continue titrating — May 2025

When to hold at a dose vs continue titrating — May 2025

gary_naperville Tue, Mar 10, 2026 at 8:41 PM 3 replies 681 viewsPage 1 of 1
gary_naperville
Member
245
1,123
Oct 2024
Naperville, IL
Mar 10, 2026 at 8:41 PM#1

Four dose steps in, holding each one the full four weeks, and I am trying to work out whether the interval is a pharmacological requirement or a tolerability convention.

What I actually want to know is why the interval is four weeks rather than two, and whether a slower ladder gets to the same place.

Numbers rather than impressions, if you have them.

9 4SleepFixSam, PurityPaulOR, MaxMetOK and 6 others
Reply Quote Save Share Report
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Mar 10, 2026 at 8:51 PM#2

This one has a reasonably settled answer, so here it is. Holding longer is the underrated move. A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component tachyphylaxes while the appetite effect persists. Escalating at week two throws that adaptation away.

Happy to go further on any of that.

8 3PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 5 others
Reply Quote Save Share Report
pam_stl
Member
267
1,123
Oct 2024
St. Louis, MO
Mar 10, 2026 at 9:01 PM#3
JennaRN said:
A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component…

That is right for the weekly injectables. For the daily agents the interval logic is different and the four-week convention does not transfer.

Last edited: Mar 11, 2026 at 2:01 AM
7 2PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 4 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Mar 10, 2026 at 9:11 PM#4
gary_naperville said:
Four dose steps in, holding each one the full four weeks, and I am trying to work out whether the interval is a pharmacological requirement or a…

Can confirm the pattern gary_naperville describes. The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks later. The end point of the ladder is set by tolerability, not by a schedule, and there is no evidence that reaching the top faster produces a better outcome.

6 1DebRD_ATL, KristenIndy, MarkLI_maint and 3 others
Reply Quote Save Share Report
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Mar 10, 2026 at 10:05 PM#5

Clinical perspective, offered as context rather than as advice.

PSA for titration users considering the 0.25mg starting dose: this dose is NOT intended for weight loss. It's a titration dose to let your body adjust. Don't be discouraged if you don't lose much in the first month.

The therapeutic dose for weight management starts at 1.7mg (semaglutide) or 5mg (tirzepatide). Be patient with the ramp-up.

5 0carl_compliance, DanielChem_CHI, marco_milano and 2 others
Reply Quote Save Share Report

Similar Threads

Micro-dosing semaglutide — is sub-therapeutic dosing effective?16 replies
Injection technique: subcutaneous depot formation and absorption8 replies
Semaglutide PK modeling — when to time your injection12 replies
Reconstitution calculator — compounded peptide dosing math7 replies
Half-life implications for missed doses — PK-based guidance5 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register